Biotransformation and bioactivation reactions – 2015 literature highlights

Drug Metabolism Reviews

Volumn 48, Issue 2, 2016, Pages 113-138

  Baillie, Thomas A ^a   Dalvie, Deepak ^b   Rietjens, Ivonne M C M ^c   Cyrus Khojasteh, S ^d  

^a UNIVERSITY OF WASHINGTON   (United States)

^b GENENTECH INC   (United States)

^c WAGENINGEN UNIVERSITY   (Netherlands)

^d PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

2015 review; Bioactivation; biotransformation; literature highlights; metabolism

Indexed keywords

ALBUMIN; ALDEHYDE OXIDASE; BENZBROMARONE; BETA ASARONE; CARCINOGEN; CYTOCHROME P450; DELAMANID; ELECTROPHILE; GDC 0623; HYDROPEROXIDE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; N ACETYL 1,4 BENZOQUINONE IMINE; NITROSAMINE; PARACETAMOL; SULFUR DERIVATIVE; UNCLASSIFIED DRUG; 4-(METHYLNITROSAMINO)-1-(3-PYRIDYL)-1-BUTAN-1-OL; 4-BROMOANILINE; 5-((ISOXAZOL-3-YLAMINO)METHYL)-3-(2,3,5-TRIFLUORO-4-(4-OXO-3,4-DIHYDROPYRIDIN-1(2H)-YL)PHENYL)OXAZOLIDIN-2-ONE; ANILINE DERIVATIVE; ANISOLE DERIVATIVE; ASARONE; AZD9819; GDC-0623; IMIDAZOLE DERIVATIVE; JNJ-38877605; N-(3-(6-(4-(1,4-DIMETHYL-3-OXOPIPERAZIN-2-YL)PHENYLAMINO)-4-METHYL-5-OXO-4,5-DIHYDROPYRAZIN-2-YL)-2-METHYLPHENYL)-4,5,6,7-TETRAHYDROBENZO(B)THIOPHENE-2-CARBOXAMIDE; NICOTINAMIDE; NITROIMIDAZOLE DERIVATIVE; OPC-67683; OXAZOLE DERIVATIVE; OXAZOLIDINONE DERIVATIVE; PEROXIDE; PYRAZINE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRIDAZINE DERIVATIVE; PYRIDINE DERIVATIVE; PYRIDONE DERIVATIVE; PYRIMIDINONE DERIVATIVE; THIOPHENE DERIVATIVE; TRIAZOLE DERIVATIVE;

DECOMPOSITION; DRUG METABOLISM; DRUG TRANSFORMATION; ENZYME MECHANISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PHARMACOKINETIC PARAMETERS; REVIEW; RING OPENING; STEREOSPECIFICITY; TIME OF FLIGHT MASS SPECTROMETRY; ANALOGS AND DERIVATIVES; ANIMAL; BIOTRANSFORMATION; HUMAN;

ACETAMINOPHEN; ANILINE COMPOUNDS; ANIMALS; ANISOLES; BENZBROMARONE; BIOTRANSFORMATION; HUMANS; IMIDAZOLES; NIACINAMIDE; NITROIMIDAZOLES; NITROSAMINES; OXAZOLES; OXAZOLIDINONES; PEROXIDES; PYRAZINES; PYRAZOLES; PYRIDAZINES; PYRIDINES; PYRIDONES; PYRIMIDINONES; THIOPHENES; TRIAZOLES;

EID: 84977502036     PISSN: 03602532     EISSN: 10979883     Source Type: Journal    
DOI: 10.1080/03602532.2016.1195404     Document Type: Review

References (68)

1. M.Akhtar, J.N.Wright, P.Lee-Robichaud (2011). A review of mechanistic studies on aromatase (CYP19) and 17alpha-hydroxylase-17,20-lyase (CYP17). J Steroid Biochem Mol Biol 125:2–12.
2. C.den Besten, P.J.van Bladeren, E.Duizer,. (1993). Cytochrome P450-mediated oxidation of pentafluorophenol to tetrafluorobenzoquinone as the primary reaction product. Chem Res Toxicol 6:674–680.
3. Y.Kitagawara, T.Ohe, K.Tachibana,. (2015). Novel bioactivation pathway of benzbromarone mediated by cytochrome P450. Drug Metab Dispos 43:1303–1306.
4. K.Kobayashi, E.Kajiwara, M.Ishikawa,. (2012). Identification ofisozymes involved in benzbromarone metabolism in human liver microsomes. Biopharm Drug Dispos 33:466–473.
5. J.J.Li, R.H.Purdy, E.H.Appelman,. (1985). Catechol formation of fluoro- and bromo-substituted estradiols by hamster liver microsomes. Evidence for dehalogenation. Mol Pharmacol 27:559–565.
6. M.G.McDonald, A.E.Rettie (2007). Sequential metabolism and bioactivation of the hepatotoxin benzbromarone: formation of glutathione adducts from a catechol intermediate. Chem Res Toxicol 20:1833–1842.
7. T.Ohe, T.Mashino, M.Hirobe (1997). Substituent elimination from p-substituted phenols by cytochrome P450. ipso-substitution by the oxygen atom of the active species. Drug Metab Dispos 25:116–122.
8. B.K.Park, N.R.Kitteringham (1994). Effects of fluorine substitution on drug metabolism: pharmacological and toxicological implications. Drug Metab Rev 26:605–643.
9. C.M.Rietjens, J.Vervoort (1992.) A new hypothesis for the mechanism for cytochrome P-450 dependent aerobic conversion of hexahalogenated benzenes to pentahalogenated phenols. Chem Res Toxicol 5:10–19. [10.1021/tx00025a004]
10. F.Varfaj, S.N.Zulkifli, H.G.Park,. (2014). Carbon–carbon bond cleavage in activation of the prodrug nabumetone. Drug Metab Dispos 42:828–838.
11. K.P.Vatsis, M.J.Coon (2002). Ipso-substitution by cytochrome P450 with conversion of p-hydroxybenzene derivatives to hydroquinone: Evidence for hydroperoxo-iron as the active oxygen species. Arch Biochem Biophys 397:119–129.
12. C.Gu, R.J.Lewis, A.S.Wells,. (2015). Lipid peroxide-mediated oxidative rearrangement of the pyrazinone carboxamide core of neutrophil elastase inhibitor AZD9819 in blood plasma samples. Drug Metab Dispos 43:1441–1449.
13. F.P.Guengerich (2001a). Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. Chem Res Toxicol 14:611–650.
14. F.P.Guengerich (2001b). Uncommon P450-catalyzed reactions. Cur Drug Metab 2:93–115.
15. F.P.Guengerich (2007). Mechanisms of cytochrome P450 substrate oxidation: MiniReview. J Biochem Mol Toxicol 21:163–168.
16. R.Singh, M.V.Silva Elipe, P.G.Pearson,. (2003). Metabolic activation of a pyrazinone-containing thrombin inhibitor. Evidence for novel biotransformation involving pyrazinone ring oxidation, rearrangement, and covalent binding to proteins. Chem Res Toxicol 16:198–207.
17. 13C-labels, mass spectrometry, and NMR. Drug Metab Dispos 31:1437–1447.
18. S.Brandange, L.Lindblom (1979). The enzyme “aldehyde oxidase” is an iminium oxidase. Reaction with nicotine delta 1'(5') iminium ion. Biochem Biophys Res Commun 91:991–996.
19. F.Fiorentini, M.Geier, C.Binda,. (2016). Biocatalytic characterization of human FMO5: unearthing Baeyer–Villiger reactions in humans. ACS Chem Biol. 11:1039–48.
20. W.G.Lai, N.Farah, G.A.Moniz, Y.N.Wong (2011). A Baeyer–Villiger oxidation specifically catalyzed by human flavin-containing monooxygenase 5. Drug Metab Dispos 39:61–70.
21. J.Meng, D.Zhong, L.Li,. (2015). Metabolism of MRX-I, a novel antibacterial oxazolidinone, in humans: The oxidative ring opening of 2,3-dihydropyridin-4-one catalyzed by non-P450 enzymes. Drug Metab Dispos 43:646–659.
22. P.J.Murphy (1973). Enzymatic oxidation of nicotine to nicotine 1'(5') iminium ion. A newly discovered intermediate in the metabolism of nicotine. J Biol Chem 248:2796–2800.
23. T.Rousu, O.Pelkonen, A.Tolonen (2009) Rapid detection and characterization of reactive drug metabolites in vitro using several isotope-labeled trapping agents and ultra-performance liquid chromatography/time-of-flight mass spectrometry. Rapid Commun Mass Spectrom 23:843–855.
24. E.Wu, T.Shinka, P.Caldera-Munoz,. (1988). Metabolic studies on the nigrostriatal toxin MPTP and its MAO B generated dihydropyridinium metabolite MPDP+. Chem Res Toxicol 1:186–194.
25. S.Xu, B.Zhu, Y.Teffera,. (2005). Metabolic activation of fluoropyrrolidine dipeptidyl peptidase-IV inhibitors by rat liver microsomes. Drug Metab Dispos 33:121–130.
26. K.E.Zhang, J.A.Naue, B.Arison, K.P.Vyas (1996). Microsomal metabolism of the 5-lipoxygenase inhibitor L-739,010: Evidence for furan bioactivation. Chem Res Toxicol 9:547–554.
27. Y.Hagiya, S.Kamata, S.Mitsuoka,. (2015). Hemizygosity of transsulfuration genes confers increased vulnerability against acetaminophen-induced hepatotoxicity in mice. Toxicol Appl Pharmacol 282:195–206.
28. T.Ida, T.Sawa, H.Ihara,. (2014). Reactive cysteine persulfides and S-polythiolation regulate oxidative stress and redox signaling. Proc Natl Acad Sci USA 111:7606–7611.
29. J.Sun, L.K.Schnackenberg, R.D.Holland,. (2008). Metabonomics evaluation of urine from rats given acute and chronic doses of acetaminophen using NMR and UPLC/MS. J. Chrom B: Anal Technol Biomed Life Sci 871:328–340.
30. S.Diamond, J.Boer, T.P.Maduskie,. (2010). Species-specific metabolism of SGX523 by aldehyde oxidase and the toxicological implications. Drug Metab Dispos 38:1277–1285.
31. J.R.Infante, T.Rugg, M.Gordon,. (2013). Unexpected renal toxicity associated with SGX523, a small molecule inhibitor of MET. Invest New Drugs 31:363–369.
32. Y.Moriwaki, T.Yamamoto, S.Takahashi,. (2001). Widespread cellular distribution of aldehyde oxidase in human tissues found by immunohistochemistry staining. Histol Histopathol 16:745–753.
33. S.Sanoh, Y.Tayama, K.Sugihara,. (2015). Significance of aldehyde oxidase during drug development: Effects on drug metabolism, pharmacokinetics, toxicity, and efficacy. Drug Metab Pharmacokinet 30:52–63.
34. D.A.Smith, R.S.Obach (2009). Metabolites in safety testing (MIST): Considerations of mechanisms of toxicity with dose, abundance, and duration of treatment. Chem Res Toxicol 22:267–279.
35. S.G.Carmella, S.Akerkar, S.S.Hecht, (1993). Metabolites of the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in smokers’ urine. Cancer Res 53:721–724.
36. S.G.Carmella, S.A.Akerkar, J.P.RichieJr., S.S.Hecht (1995). Intraindividual and interindividual differences in metabolites of the tobacco-specific lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in smokers’ urine. Cancer Epidemiol Biomarkers Prev 4:635–642.
37. S.G.Carmella, K.-A.Le, P.Upadhyaya, S.S.Hecht (2002). Analysis of N- and O-glucuronides of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) in human urine. Chem Res Toxicol 15:545–550.
38. S.S.Hecht, N.Trushin, C.A.Reid-Quinn,. (1993). Metabolism of the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in the patas monkey: Pharmacokinetics and characterization of glucuronide metabolites. Carcinogenesis 14:229–236.
39. Y.Lao, N.Yu, F.Kassie, P.W.Villalta, S.S.Hecht (2007). Formation and accumulation of pyridyloxobutyl DNA adducts in F344 rats chronically treated with 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and enantiomers of its metabolite, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol. Chem Res Toxicol 20:235–245.
40. E.Richter, J.Engl, S.Friesenegger, A.R.Tricker (2009). Biotransformation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in lung tissue from mouse, rat, hamster, and man. Chem Res Toxicol 22:1008–1017.
41. I.M.C.M.Rietjens, J.Louisse, A.Punt (2011). Tutorial on physiologically based kinetic (PBK) modelling in molecular nutrition and food research. Mol Nutr Food Res 55:941–956.
42. P.Upadhyaya, P.M.Kenney, J.B.Hochalter,. (1999). Tumorigenicity and metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol enantiomers and metabolites in the A/J mouse. Carcinogenesis 20:1577–1582.
43. S.Zhang, M.Wang, P.W.Villalta,. (2009). Analysis of pyridyloxobutyl and pyridylhydroxybutyl DNA adducts in extrahepatic tissues of F344 rats treated chronically with 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and enantiomers of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol. Chem Res Toxicol 22:926–936.
44. C.H.Huang, F.R.Ren, G.Q.Shan,. (2015). Molecular mechanism of metal-independent decomposition of organic hydroperoxides by halogenated quinoid carcinogens and the potential biological implications. Chem Res Toxicol 28:831–837.
45. F.Qin, Y.Y.Zhao, Y.L.Zhao,. (2010) A toxic disinfection by-product, 2,6-dichloro-1,4-benzoquinone, identified in drinking water. Angew Chem Int Ed 49:790–792.
46. Y.L.Zhao, F.Qin, J.M.Boyd,. (2010) Characterization and determination of chloro- and bromo-benzoquinones as new chlorination disinfection byproducts in drinking water. Anal Chem 82:4599–4605.
47. E.W.Boberg, E.C.Miller, J.A.Miller,. (1983). Strong evidence from studies with Brachymorphic mice and pentachlorophenol that 1'-sulfooxysafrole is the major ultimate electrophilic and carcinogenic metabolite of 1'-hydroxysafrole in mouse liver. Cancer Res 43:5163–5173.
48. P.Borchert, J.A.Miller, E.C.Miller, T.K.Shires (1973). 1'-Hydroxysafrole a proximate carcinogenic metabolite of safrole in the rat and mouse. Cancer Res 33:590–600.
49. A.T.Cartus, S.Stegmüller, N.Simson,. (2015). Hepatic metabolism of carcinogenic β-asarone. Chem Res Toxicol 28:1760–1773.
50. COE (Committee of Experts on Flavouring Substances of the Council of Europe). (2005). The 1st report on active principles (Constituents of Toxicological Concern) contained in natural sources of flavourings. Available from: http://www.coe.int/t/e/social_cohesion/soc%2Dsp/public_health/flavouring_substances/Active%20principles.pdf.
51. N.R.Drinkwater, E.C.Miller, J.A.Miller, H.C.Pitot (1976). Hepatocarcinogenicity of estragole (1-allyl-4-methoxybenzene) and 1’-hydroxyestragole in the mouse and mutagenicity of 1'-acetoxyestragole in bacteria. J Natl Cancer Inst 57:1323–1331.
52. I.M.C.M.Rietjens, T.B.Adams, M.Bastaki,. (2014). The impact of structural and metabolic variation on the toxicity and carcinogenicity of hydroxy- and alkoxy-substituted allyl- and propenylbenzenes. Chem Res Toxicol 27:1092–1103.
53. SCF (Scientific Committee on Food). (2002). Opinion of the Scientific Committee on food on the presence of β-asarone in flavourings and other food ingredients with flavouring properties, SCF/CS/FLAV/FLAVOUR/9 ADD1 Final. Available from: http://ec.europa.eu/food/fs/sc/scf/out111_en.pdf.
54. R.Truhaut, B.Le Bourhis, M.Attia,. (1989) Chronic toxicity/carcinogenicity study of trans-anethole in rats. Fd Chem Toxico 27:11704–11720.
55. R.W.Wiseman, T.R.Fennell, J.A.Miller, E.C.Miller (1985). Further characterization of the DNA adducts formed by electrophilic esters of the hepatocarcinogens 1'-hydroxysafrole and 1'-hydroxyestragole in vitro and in mouse liver in vivo, including new adducts at C-8 and N-7 of guanine residues. Cancer Res 45:3096–3105.
56. R.W.Wiseman, E.C.Miller, J.A.Miller, A.Liem (1987). Structure-activity studies of the hepatocarcinogenicities of alkenylbenzene derivatives related to estragole and safrole on administration to preweanling male C57BL/6J × C3H/HeJ F1 mice. Cancer Res 47:2275–2278.
57. P.G.Wislocki, P.Borchert, J.A.Miller, E.C.Miller (1976). The metabolic activation of the carcinogen 1'-hydroxysafrole in vivo and in vitro and the electrophilic reactivities of possible ultimate carcinogens. Cancer Res 36:1686–1695.
58. P.G.Wislocki, E.C.Miller, J.A.Miller,. (1977) Carcinogenic and mutagenic activities of safrole, 1'-hydroxysafrole, and some known or possible metabolites. Cancer Res 37:1883–1891.
59. M.Matsumoto, H.Hashizume, T.Tomishige,. (2006). OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med 3:e466.
60. N.Ohta, Y.Kurono, K.Ikeda (1983). Esterase-like activity of human serum albumin II: reaction with N-trans-cinnamoylimidazoles. J Pharm Sci 72:385–8.
61. I.D.Olaru, F.von Groote-Bidlingmaier, J.Heyckendorf,. (2014). Novel drugs against tuberculosis: a clinician’s perspective. Eur Respir J 45:1119–1131.
62. EMA summary. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002552/WC500166232.pdf
63. D.R.Noble, D.L.H.Williams (2001). Formation and reactions of S-nitroso proteins. J Chem Soc Perkin Trans 2:13–17.
64. P.A.Wabnitz, D.Mitchell, D.A.Wabnitz (2004). In Vitro and in vivo metabolism of the anti-cancer agent CI-1040, a MEK inhibitor, in rat, monkey, and human. Pharm Res 21:1670–1679.
65. J.T.Barr, K.Choughule, J.P.Jones (2014). Enzyme kinetics, inhibition, and regioselectivity of aldehyde oxidase. Methods Mol Biol 1113:167–186.
66. E.Garattini, M.Terao (2013). Aldehyde oxidase and its importance in novel drug discovery: present and future challenges. Expert Opin Drug Discov 8:641–654.
67. A.H.Gordon, D.E.Green, V.Subrahmanyan (1940). Liver aldehyde oxidase. Biochem J 34:764–74.
68. S.Sanoh, Y.Tayama, K.Sugihara,. (2015). Significance of aldehyde oxidase during drug development: Effects on drug metabolism, pharmacokinetics, toxicity, and efficacy. Drug Metab Pharmacokinet 30:52–63.